Thureau, Sébastien
Marchesi, Vincent
Vieillard, Marie-Hélène
Perrier, Lionel
Lisbona, Albert
Leheurteur, Marianne
Tredaniel, Jean
Culine, Stéphane
Dubray, Bernard
Bonnet, Naïma
Asselain, Bernard
Salleron, Julia
Faivre, Jean-Christophe http://orcid.org/0000-0002-2617-3562
Funding for this research was provided by:
Ministère des Finances et des Comptes Publics (PHRC K 15 149)
Article History
Received: 2 October 2020
Accepted: 21 January 2021
First Online: 4 February 2021
Ethics approval and consent to participate
: French ethics committee (CPP Nord-Ouest I) has approved this protocol on October 13th 2016 (reference number: CPP 02/016/2016).Patient information and informed consent from the patient must be handled in accordance with the French regulation. Prior to the participation of a patient in the trial, this patient will be informed both verbally and in writing about the objectives of the trial, its methods, anticipated benefits and potential risks and the discomfort to which they may be exposed. The informed consent form for study and ancillaries studies, must be personally dated and signed by the patient and investigator.The manuscript has undergone peer review by the funding body.
: Not applicable.
: The authors declare that they have no competing interests.